Hypertensive disorders of pregnancy, particularly preeclampsia, are a leading cause of maternal and perinatal morbidity. While antihypertensive therapy is recommended, clinical uncertainty persists regarding the optimal agent to maximize maternal safety while minimizing adverse neonatal outcomes such as neonatal intensive care unit (NICU) admission. This review aimed to evaluate the comparative effectiveness and safety of pharmacological antihypertensive agents versus standard care or placebo in the management of hypertensive disorders of pregnancy through a network meta-analysis (NMA). A systematic review and frequentist random-effects NMA of randomized controlled trials (RCTs) was conducted. Major databases were searched for RCTs comparing antihypertensive agents (labetalol, nifedipine, methyldopa, hydralazine, prazosin) and controls. The primary neonatal outcome evaluated in this network was NICU admission. Risk of bias was assessed using the Cochrane RoB 2 tool, and the certainty of evidence was evaluated using the GRADE framework. Twenty-five RCTs were included in the qualitative and quantitative synthesis. The network geometry was anchored by labetalol and nifedipine. In the NMA, no individual antihypertensive agent demonstrated a statistically significant reduction in the risk of NICU admission compared to labetalol. However, probabilistic ranking (P-scores) identified methyldopa (P-score = 0.859) and hydralazine (0.791) as the most favourable interventions for minimizing NICU admissions. Nifedipine showed a slightly elevated, though non-significant, risk profile compared to labetalol (RR 1.09, 95% CI 0.80-1.49). The placebo and standard care ranked lowest. The overall certainty of evidence ranged from moderate to very low due to imprecision and indirectness. Active pharmacological management of hypertension in pregnancy is superior to placebo or standard care. While labetalol and nifedipine remain mainstays for acute blood pressure control, methyldopa and hydralazine probabilistically rank higher for minimizing NICU admissions. These findings support individualized antihypertensive selection based on clinical acuity and maternal-fetal hemodynamics.
preeclampsiahypertensive disorders of pregnancyantihypertensive drugslabetalol
Systemic lupus erythematosus (SlE) is a chronic, multisystem, autoimmune disease that predominantly affects women during their reproductive years.Pregnancy in women with SlE is no longer considered uniformly prohibitive; however, it remains a high-risk clinical scenario due to maternal disease activity, lupus nephritis, antiphospholipid antibodies, chronic organ damage, and treatment-related factors that can adversely affect both maternal and fetal outcomes.Current evidence indicates that the risk of flare is highest in women who conceive with an active disease, discontinue effective therapy, or have a history of major organ involvement.at the same time, pregnancy introduces diagnostic complexity due to physiological gestational changes which may mimic lupus activity, particularly in hematological, renal and vascular domains.Maternal complications include preeclampsia, thromboembolism, infection, lupus nephritis exacerbation and postpartum flare, whereas fetal complications include miscarriage, fetal growth restriction, prematurity, neonatal lupus and congenital heart block in anti-ro/SSa-or anti-la/SSB-positive pregnancies.optimal management begins prior to conception and requires multidisciplinary care, risk stratification, medication optimization and structured maternal-fetal surveillance throughout pregnancy and the puerperium.the present narrative review summarizes contemporary evidence on the immunopathogenesis, preconception assessment, maternal and fetal risks, and therapeutic management of SlE in pregnancy, with an emphasis on clinically applicable strategies that improve patient outcomzes.Contents 1. Introduction 2. Pathogenesis of SlE 3. Effects of pregnancy on SlE 4. Pre-pregnancy counseling and considerations 5. Pre-pregnancy analyses in patients with SlE 6. Contraceptives in patients with SlE 7. Infertility in patients with SlE 8. Effects of SlE on pregnancy 9. Maternal complications associated with SlE 10.Placental disease in pregnancy in women with SlE and fetal complications of SlE 11.Puerperium 12. Medications for SlE during pregnancy 13.Biologics and emerging therapies 14.Conclusion
This systematic review aimed to evaluate the prevalence, awareness, risk factors, and outcomes of preeclampsia among women in Saudi Arabia.In accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines, we searched PubMed, Web of Science, and Cochrane databases, focusing on studies published between 1999 and 2024. We included observational studies conducted in Saudi Arabia reporting the risk factors, prevalence, and outcomes of preeclampsia.Overall, 21 studies were included in the analysis, of which 15 analyzed prevalence. The prevalence of preeclampsia in Saudi Arabia was 4.80%, with higher rates reported in cross-sectional studies (9.52%). Only 27% of women demonstrated preeclampsia awareness, and the key identified risk factors included serum lead, immunoglobulin A nephropathy, and calcium, magnesium, and zinc deficiencies. Adverse maternal outcomes included hemolysis, elevated liver enzymes, and low platelet syndrome and eclamptic seizures, whereas fetuses faced significant risks, including stillbirth, prematurity, and intrauterine growth restriction (IUGR).Preeclampsia poses a significant health burden in Saudi Arabia, which is compounded by limited public awareness and critical risk factors. These findings underscore the urgent need for improved preeclampsia screening and education in expectant mothers. Enhanced antenatal care and public health initiatives targeting preeclampsia awareness may improve maternal and fetal outcomes and reduce the long-term health burdens associated with this condition.
Microbes and Infectious Diseases /Microbes and Infectious Diseases · مجلد 0 (0) · 0-0
Background: Pregnant women with the novel coronavirus disease (COVID-19) are more likely than non-pregnant women to develop severe COVID-19 complications. In addition, COVID-19 is linked to unfavorable pregnancy outcomes. Due to the lack of effective COVID-19 treatment, it is critical to assess geographic differences and trends in current clinical care and the effect of COVID-19 on pregnant women. This review aims to evaluate maternal and neonatal outcomes in COVID-19 pregnancies. We searched the Medline database for research papers from January 2019 to December 31, 2021. Eleven studies of systematic, meta-analysis, review, and cohort designs were included with searched keywords {Pregnancy AND COVID [MeSH Terms]}. This study summarizes the maternal characteristics, vertical Transmission, maternal and neonatal outcomes, the rate of cesarean section, comorbidities, mechanical ventilation, ICU admission rate, mode of delivery, type of anesthesia, the average hospital length of stay (HLOS), the extracorporeal membrane oxygenation (ECMO), preeclampsia, pregnancy-induced hypertension, chest x‐ray and CT scan findings, treatments, and outcomes over time.
Saudi Critical Care Journal · مجلد 4 (3) · 103-103
Objective: Failure of health-care providers to have sufficient knowledge and prevention measures of gestational hypertension leads to an increased rate of complications during pregnancy that may lead to the loss of the fetus. The study aims to determine the level of the nurses' knowledge working in primary health-care (PHC) centers regarding gestational hypertension disorders in Riyadh city. Subjects and Methods: A descriptive correlational, nonexperimental study design was conducted at 6 PHC centers using a self-administered questionnaire for nurses (n = 257). Results: Nurses had inadequate knowledge about the essential key items of gestational hypertension disorders. Almost half of the nurses (44%) lacked knowledge about how to assess the fetal condition in case of gestational hypertension, and 57.98% of the sample had difficulty in identifying the signs and symptoms of mild preeclampsia. The majority of the sample (70.42%) had unsatisfactory knowledge about essential drugs for the treatment of preeclampsia; 54.08% of the nurses experienced insufficient knowledge about their role before the administration of magnesium sulfate drugs. In addition, study results show that there was a lack of knowledge on the appropriate management of preeclampsia among the majority study participants (98.83%) with a total knowledge mean score (19.09, 63.63%). Conclusion: Primary care nurses lacked the needed knowledge to identify and provide preventive care to women experiencing gestational hypertension. Furthermore, there was a lack of knowledge in regard to identifying the complications of preeclampsia. The nurses are accountable for the quality of maternity care, and a maternity training program must be considered.
gestational hypertensionpreeclampsiaprimary care nursesnursing knowledge